Requip should soon be available in an extended release tablet. The United States Food and Drug Administration issued an "approvable" letter to Requip's maker GlaxoSmithKline allowing them to market the improved product.
Read Full Article
If you are reading this you or someone close to you probably has something in common with Time Magazine columnist Michael Kinsley: Parkinson's disease. You probably also share the same hope that stem cell research will find a cure for Parkinson's disease someday.
Read Full Article
This week's news that scientists can create embryonic stem cells from skin cells could be beneficial to people with Parkinson's disease. It may eliminate ethical hurdles, and it has the potential to make stem cells more compatible with patients.
Read Full Article
Embryonic stem cells are graduating from the laboratory and beginning human clinical trials.
A CNNMoney.com story discusses a number of stem cell therapies that companies will present to the U.S. Food and Drug Administration in the coming months. Many of them will enter clinical trials and cross a new frontier—the human body. To date there have been no embryonic stem cell experiments on humans.
Read Full Article
A team of scientists has announced proof that the chemical DOPAL starts the chain reaction that causes Parkinson's disease.
The St. Louis University researchers discovered that dopamine itself actually plays a role in destroying the cells that produce it. DOPAL is one of many possible residues that remains after dopamine is depleted. It happens to be a poisonous leftover.
Read Full Article
Four gene therapy treatments are undergoing testing. These therapies seek to repair the parts of the brain damaged by Parkinson's disease.
Read Full Article
Too much optimism in the case of preventing Parkinson's disease can lead to false hope. An update on research into preventing PD clears up some confusion.
Read Full Article
A certain genetic mutation that may determine whether a person will develop Parkinson's disease may also play a hand in early-onset PD.
Read Full Article
By Matt Nilsen
In February we wrote about the Parkinson's medication Duodopa and its success in clinical use and research trials. It is available in Sweden and other Euopean countries, but is still in the approval process in the United States. Duodopa is levodopa and carbidopa administered into the small intestine. There is evidence that many patients have remarkable results when the medication skips the stomach and goes straight into the intestines.
Read Full Article
Isradipine is already on the market to help people maintain heart health. However, in animal experiments, scientists found that it helped ward off attacks from chemicals that can damage dopamine producing neurons.
Read Full Article
